On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates

Table 2 Univariate and multivariate analyses of progression-free survival in the exploratory cohort

Index	Univariate analysis		Multivariate analysis
Index	HR (95% CI)	P value	HR (95% CI)	P value
Age
≥ 65 years old	0.746 (0.433–1.285)	0.290
< 65 years old	Reference
Race
White	Reference
Others	0.786 (0.109–5.662)	0.811
Initial stage
III–IV	0.785 (0.515–1.197)	0.261
Others	Reference
Recurrence type
Newly diagnosed	0.664 (0.425–1.038)	0.072
Others	Reference
Disease-free interval
Newly metastatic disease	0.625 (0.404–0.966)	0.035	0.574 (0.367–0.898)	0.015
Others	Reference		Reference
Disease site
Visceral	1.771 (1.129–2.778)	0.013	1.847 (1.167–2.925)	0.009
Nonvisceral	Reference		Reference
Bone-only metastasis	0.683 (0.385–1.211)	0.192
Others	Reference
Number of disease sites
≥ 3	1.609 (1.055–2.455)	0.027	1.579 (1.017–2.450)	0.042
1, 2	Reference		Reference
Derived neutrophil-to-lymphocyte ratio^a
≥ 1.04	3.369 (2.134–5.320)	< 0.001	3.314 (2.090–5.256)	< 0.001
< 1.04	Reference		Reference

ISSN: 1465-542X